View Older Stories View More Recent Stories

Nov 9, 2018 07:07AM Ionis Pharmaceuticals to Host Investor Day
Nov 8, 2018 07:37AM Akcea Therapeutics (AKCA), Ionis (IONS) Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at AHA
Nov 8, 2018 07:00AM Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
Nov 8, 2018 07:00AM Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
Nov 7, 2018 07:00AM Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 6, 2018 07:00AM Ionis Reports Third Quarter 2018 Financial Results
Oct 31, 2018 07:00AM Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting
Oct 24, 2018 07:00AM Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast
Oct 23, 2018 07:00AM Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science
Oct 22, 2018 08:47AM Ionis Pharmaceuticals (IONS) Reports New Phase 1b/2 Trial Data on Danvatirsen (formerly IONIS-STAT3-2.5Rx, aka AZD9150) at ESMO 2018
Oct 22, 2018 08:45AM Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology
Oct 10, 2018 09:09AM Ionis Pharmaceuticals (IONS) Enters Pact with Roche to Develop IONIS-FB-L Rx for Complement-Mediated
Oct 10, 2018 09:07AM Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Oct 8, 2018 06:16AM Akcea (AKCA), Ionis (IONS) Receive FDA Approval of TEGSEDI (Earlier)
Oct 8, 2018 05:58AM Biogen (BIIB) Reports New Interim Study Results from NURTURE
Oct 6, 2018 07:30AM New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
Oct 5, 2018 05:32PM Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Oct 5, 2018 05:32PM Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Oct 4, 2018 04:05PM Akcea Therapeutics (AKCA) Announce Approval of TEGSEDI in Canada
Oct 4, 2018 04:05PM Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
Oct 4, 2018 04:05PM Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
Oct 4, 2018 04:05PM Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
Jun 13, 2018 07:30AM Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Jun 13, 2018 07:30AM Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Jun 13, 2018 07:30AM Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Apr 23, 2018 07:33AM Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN Meetings
Apr 23, 2018 07:30AM New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants
Apr 20, 2018 06:54AM Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug Development
Apr 20, 2018 06:30AM Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Mar 12, 2018 07:30AM New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)
Feb 14, 2018 05:09PM Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published SPINRAZA (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Feb 14, 2018 05:01PM The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Dec 19, 2017 05:38PM Biogen (BIIB) and Ionis (IONS) Enter Agreement to Identify Novel Therapies for Treatment of SMA
Dec 19, 2017 04:06PM Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
Nov 1, 2017 05:07PM Biogen (BIIB), Ionis (IONS) Announces NEJM Publishes First Phase 3 Study Results of SPINRAZA for Treatment of Spinal Muscular Atrophy
Nov 1, 2017 05:06PM The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
Oct 5, 2017 07:32AM Biogen (BIIB) Reports SPINRAZA (Nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function
Oct 5, 2017 07:30AM Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Jun 29, 2017 07:33AM Biogen (BIIB) Says New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA in SMA
Jun 29, 2017 07:30AM New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Jun 1, 2017 07:31AM Biogen (BIIB) Says SPINRAZA Approved in EU as First Treatment for Spinal Muscular Atrophy
Jun 1, 2017 07:30AM SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
Apr 24, 2017 07:32AM Biogen (BIIB) Says Final Phase 3 Study Data Show SPINRAZA Significantly Improved Motor Function in Children with Later-Onset SMA
Apr 24, 2017 07:30AM Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Apr 21, 2017 02:02PM Biogen (BIIB) Report Positive CHMP Opinion on SPINRAZA for Treatment of Spinal Muscular Atrophy
Apr 21, 2017 02:00PM Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Jan 13, 2017 07:33AM Biogen (BIIB) Phase 3 Data on SPINRAZA Shows Significantly Reduced Risk of Death in SMA
Jan 13, 2017 07:30AM New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Dec 27, 2016 05:45AM Biogen (BIIB) Receives FDA Approval for SPINRAZA to Treat SMA (IONS)
Dec 23, 2016 05:08PM U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
View More Recent Stories View Older Stories